Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 153.55M shares rose 15.4% year over year, ahead of the +13.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 13.1% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.4% holds above the trailing-twelve-month pace of +13.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
153.55M+13.1% QoQ
Last fiscal yearDec 2025
135.72M+18.6% YoY
LTMMar 2026
139.28M+13.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.4%——
1 year+18.6%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
135.72M USD
Year-over-year change
+18.6%
4-year CAGR
+10.8%

Weighted Avg Shares vs competitors

How CNTA compares with its peers on the latest reported figures

  • CNTA's LTM Mar 2026 weighted avg shares of 139.28M shares is the 3rd highest of the 10 companies compared; the peer median is 91.49M shares.
  • Its year-over-year change of +13.5% is the 8th highest of 10, against a peer median of +16.1%.
  • Over three fiscal years its annual growth of +13.3% compares with a peer median of +12.1%.
CNTA Competitors Peer median
Weighted Avg Shares for CNTA and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
CNTACentessa Pharmaceuticals plcLTM Mar 2026139.28M +13.5%+13.3%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
CGONCG Oncology, Inc. Common stockLTM Sep 202684.72M +15.3%+5.1%
APGEApogee Therapeutics, Inc.LTM Jun 202666.14M +15.7%+6.2%
CELCCelcuity Inc.LTM Jun 202651.65M +19.9%+50.5%
Peer median (excluding CNTA) 91.49M+16.1%+12.1%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.